TENX (Tenax Therapeutics) Tariff Resilience Score: 4/10 (As of Jul. 06, 2026)


TENX Tenax Therapeutics Inc TENX
22 GF Score
Price $15.49
! 3 Warning Signs
View Full Analysis

What is Tenax Therapeutics Tariff Resilience Score?

Tenax Therapeutics TENX +16.42% 22 Tariff Resilience Score is 4 as of Jul. 06, 2026. GuruFocus rates TENX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,369 Biotechnology companies, Tenax Therapeutics ranks better than 52.52% on this metric.

Tenax Therapeutics has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Tenax Therapeutics has Tenax Therapeutics is vulnerable due to its reliance on imported raw materials and international sales. Previous tariffs have increased costs, and the company has limited pricing power. While alternative suppliers exist, switching costs are high, impacting resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Tenax Therapeutics might have Average Resilient.

Tenax Therapeutics  (NAS:TENX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Tenax Therapeutics Tariff Resilience Score Related Terms

TENX vs RCKT, AVIR, VNDA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Tenax Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenax Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's Tariff Resilience Score falls into.


TENX
22GF Score
Tenax Therapeutics Inc TENX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Tenax Therapeutics (TENX) has a Tariff Resilience Score of 4 as of Jul. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Tenax Therapeutics ranks #650 out of 1369 companies in the Biotechnology industry, placing it in the top 47.5%.
Is Tenax Therapeutics' Tariff Resilience Score too high?
Tenax Therapeutics' current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. Tenax Therapeutics' value of 4 is 0% at this industry median. Based on the distribution chart, Tenax Therapeutics ranks #650 out of 1369 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' Tariff Resilience Score compare to RCKT and AVIR?
According to the Biotechnology industry distribution chart, Tenax Therapeutics ranks #650 out of 1369 companies for Tariff Resilience Score. This puts Tenax Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Tenax Therapeutics' value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tenax Therapeutics's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenax Therapeutics's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (TENX) has a current Tariff Resilience Score of 4. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. Tenax Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current Tariff Resilience Score is 4 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenax Therapeutics Business Description

Other Exchanges YBO0:Germany
Address 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score

Get the complete analysis for TENX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.49
Price